PC
IMVT icon

Polar Capital’s Immunovant IMVT Stock Holding History

Polar Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$55.2M Sell
1,569,212
-200,466
-11% -$6.03M 0.41% 72
2020
Q2 		$43.1M Buy
1,769,678
+1,319,678
+293% +$28.3M 0.37% 81
2020
Q1 		$7M Buy
450,000
+56,250
+14% +$846K 0.08% 187
2019
Q4 		$6.25M Buy
+393,750
New +$4.41M 0.05% 224

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital's IMVT Position: Q3 2020 in Review

Polar Capital reduced its Immunovant (IMVT) stake by 11% in Q3 2020, selling an estimated $6.03M and leaving 1,569,212 shares worth $55.2M. The position accounts for 0.41% of the portfolio, ranked #72.

Polar Capital first reported a position in IMVT in Q4 2019 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold IMVT as of Q3 2020.

  • Polar Capital held 1,569,212 shares of Immunovant worth $55.2M as of Q3 2020.
  • Polar Capital sold 200,466 Immunovant shares in Q3 2020, an estimated $6.03M.
  • Immunovant made up 0.41% of Polar Capital's portfolio in Q3 2020, its #72 holding.
  • Polar Capital first reported a position in Immunovant in Q4 2019 and has held it in 4 quarters since.
  • 115 funds tracked by Wall St. Rank held Immunovant as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.